SOST and kidney failure: An important advantage of the present study design was the exclusion of diseases and drugs that may interfere in bone metabolism since kidney failure, hyperparathyroidism [27] and bisphosphonates [28] could regulate sclerostin expression in osteocytes and consequently affect the sclerostin serum levels.